Literature DB >> 27531680

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

Cor H J Lamers1, Rebecca Wijers1, Cornelis A M van Bergen2, Judith A E Somers3, Eric Braakman4, Jan Willem Gratama1, Reno Debets1, J H Frederik Falkenburg2, Jan J Cornelissen4.   

Abstract

Although double umbilical cord blood transplantation (dUCBT) in adult patients may be associated with less graft failure compared with single UCBT, hematopoietic recovery generally originates from a single cord blood unit (CBU). CBU predominance is still incompletely understood. We recently showed that blood CD4+ T-cell numbers rapidly increase after dUCBT, and early CD4+ T-cell chimerism predicts for graft predominance. Given the frequent HLA class II allele mismatches between CBUs in dUCBT, we hypothesized that alloreactive HLA class II-specific CD4+ T cells from the "winning" CBU may contribute to rejection of the "loser" CBU. We evaluated whether CD4+ T cells originating from the predominant (PD)-CBU would recognize HLA class II allele mismatches, expressed by the nonengrafting (NE)-CBU. Alloreactive effector CD4+ T cells toward 1 or more mismatched HLA class II alleles of the NE-CBU were detected in 11 of 11 patients, with reactivity toward 29 of 33 (88%) tested mismatches, and the strongest reactivity toward DR and DQ alleles early after dUCBT. Mismatched HLA class II allele-specific CD4+ T cells recognized primary leukemic cells when the mismatched HLA class II allele was shared between NE-CBU and patient. Our results suggest that cytotoxicity exerted by CD4+ T cells from the PD-CBU drives the rapid rejection of the NE-CBU, whose alloreactive effect might also contribute to graft-versus-leukemia.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27531680     DOI: 10.1182/blood-2016-06-718619

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

2.  Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.

Authors:  Scott R Solomon; Andrew St Martin; Mei-Jie Zhang; Karen Ballen; Asad Bashey; Minoo Battiwalla; Lee Ann Baxter-Lowe; Claudio Brunstein; Saurabh Chhabra; Miguel Angel Diaz Perez; Ephraim J Fuchs; Siddhartha Ganguly; Nancy Hardy; Peiman Hematti; Joseph McGuirk; Edward Peres; Olle Ringden; David Rizzieri; Rizwan Romee; Melhem Solh; David Szwajcer; Marjolein van der Poel; Edmund Waller; Basem M William; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-07       Impact factor: 5.742

Review 3.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

Review 4.  Graft predominance after double umbilical cord blood transplantation: a review.

Authors:  Jan J Cornelissen; Burak Kalin; Cor H J Lamers
Journal:  Stem Cell Investig       Date:  2017-05-26

5.  Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.

Authors:  Huidong Guo; Ying-Jun Chang; Yan Hong; Lan-Ping Xu; Yu Wang; Xiao-Hui Zhang; Ming Wang; Huan Chen; Yu-Hong Chen; Feng-Rong Wang; Yu-Qian Sun; Chen-Hua Yan; Fei-Fei Tang; Xiao-Dong Mo; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Cell Mol Immunol       Date:  2021-01-06       Impact factor: 11.530

6.  Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.

Authors:  Frédéric Baron; Annalisa Ruggeri; Eric Beohou; Myriam Labopin; Mohamad Mohty; Didier Blaise; Jan J Cornelissen; Patrice Chevallier; Guillermo Sanz; Eefke Petersen; Bipin N Savani; Eliane Gluckman; Arnon Nagler
Journal:  J Hematol Oncol       Date:  2017-06-21       Impact factor: 17.388

7.  Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia.

Authors:  Ronak H Mistry; Elizabeth O Hexner; James K Mangan
Journal:  Case Rep Hematol       Date:  2019-09-11

8.  Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients.

Authors:  Bas Weenink; Mandy van Brakel; Rebecca Wijers; Peter A E Sillevis Smitt; Pim J French; Reno Debets
Journal:  J Neurooncol       Date:  2019-06-25       Impact factor: 4.506

9.  Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.

Authors:  Pauline L de Goeje; Yarne Klaver; Margaretha E H Kaijen-Lambers; Anton W Langerak; Heleen Vroman; André Kunert; Cor H J Lamers; Joachim G J V Aerts; Reno Debets; Rudi W Hendriks
Journal:  Front Immunol       Date:  2018-09-07       Impact factor: 7.561

Review 10.  T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.

Authors:  Valérie Janelle; Caroline Rulleau; Simon Del Testa; Cédric Carli; Jean-Sébastien Delisle
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.